aeterna zentaris gmb: Live & Latest News Updates : Vimarsana.com
–
In collaboration, Aeterna and The University of Sheffield, UK have selected the development candidate AEZS-150, a parathyroid hormone (PTH) fusion polypeptide to start the formal preclinical development for potentially enabling the first in human clinical study.
AEZS-150 has the potential to become a new therapeutic treatment option of primary hypoparathyroidism.
CHARLESTON, S.C., May 06, 2021 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) through its wholly-owned subsidiary Aeterna Zentaris GmbH, (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products, today announced that, in consultation with The University of Sheffield, UK (the “University”), Aeterna has selected AEZS-150 as the lead candidate in the Company’s delayed clearance parathyroid hormone fusion polypeptides (DC-PTH) program. Aeterna will now start the formal preclinical development of AEZS-150 in preparation for a potential IND filing for conducting the first in-human clinical study of AEZS-150. AEZS-150 is being developed with the goal of providing a potential new treatment option of primary hypoparathyroidism in adults.
CanadaUnited-kingdomCanadianJenene-thomasAeterna-zentaris-gmbRichardj-rossKlaus-pauliniUnited-kingdom-the-universityLinkedinAeterna-zentarisCompany-on-twitterEuropean-commission–
In collaboration, Aeterna and The University of Sheffield, UK have selected the development candidate AEZS-150, a parathyroid hormone (PTH) fusion polypeptide to start the formal preclinical development for potentially enabling the first in human clinical study.
AEZS-150 has the potential to become a new therapeutic treatment option of primary hypoparathyroidism.
CHARLESTON, S.C., May 06, 2021 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) through its wholly-owned subsidiary Aeterna Zentaris GmbH, (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products, today announced that, in consultation with The University of Sheffield, UK (the “University”), Aeterna has selected AEZS-150 as the lead candidate in the Company’s delayed clearance parathyroid hormone fusion polypeptides (DC-PTH) program. Aeterna will now start the formal preclinical development of AEZS-150 in preparation for a potential IND filing for conducting the first in-human clinical study of AEZS-150. AEZS-150 is being developed with the goal of providing a potential new treatment option of primary hypoparathyroidism in adults.
United-kingdomRichardj-rossAeterna-zentaris-gmbKlaus-pauliniUnited-kingdom-the-universityLinkedinAeterna-zentarisCompany-on-twitterEuropean-commissionNasdaqUniversity-of-sheffieldAeterna-zentaris-incDGAP-News: Atriva Therapeutics GmbH: Atriva Therapeutics Announces Changes to Management
Atriva Therapeutics Announces Changes to Management
13.04.2021 / 09:30
Atriva Therapeutics Announces Changes to Management
- Olaf Althaus appointed Chief Financial Officer
- Stephan Stenglein, M.D., recently joined as Chief Medical Officer
- Proven track record and 20+ years of experience in their respective fields of expertise
Tübingen (Germany), April 13, 2021 - Atriva Therapeutics GmbH, a biopharmaceutical company that is pioneering the development of host-targeting antiviral therapies, today announced two changes to its management team. Olaf Althaus was appointed Chief Financial Officer, effective May 2020, while Stephan Stenglein, M.D., was named Chief Medical Officer, effective February 2021.
Frankfurt-am-mainHessenGermanyHaasbachNordrhein-westfalenLondonCity-ofUnited-kingdomEva-bauer-raimund-gabrielOlaf-althausStephan-stengleinKostenloser-wertpapierhandelAeterna Zentaris Continues to Demonstrate Pipeline Expansion – Announces the Initiation of Its Preclinical Program for the Potential Treatment of Primary Hypoparathyroidism
March 11, 2021 08:05 ET | Source: Aeterna Zentaris Inc Aeterna Zentaris Inc Montreal CANADA
– Company obtains an exclusive license from The University of Sheffield, UK to intellectual property relating to parathyroid hormone (PTH) fusion polypeptides covering the field of human use which will initially be studied by Aeterna for the potential therapeutic treatment of primary hypoparathyroidism
– Continued execution on growth strategy to establish a diversified, yet focused, pipeline of development assets leveraging the Company’s expertise and experience
CHARLESTON, S.C., March 11, 2021 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) through its wholly-owned subsidiary Aeterna Zentaris GmbH, (“Aeterna” or the “Company”), a specialty biopharmaceutical company commercializing and developing therapeutics and diagnostic tests, today announced that it is continuing to expand its development pipeline by initiating a preclinical development program to develop parathyroid hormone fusion polypeptides (PTH) with delayed clearance based on proprietary intellectual property exclusively licensed by Aeterna from The University of Sheffield, UK (the “University”).
United-statesUnited-kingdomIsraelPalestinianAeterna-zentaris-gmbRichardj-rossKlaus-pauliniBoeingAeterna-zentarisMegapharm-ltdNasdaqAeterna-zentaris-inc